Prognostic Value of the MAGNIMS Score and its Application in Clinical Outcome Assessment of Disease Modifying Therapy in Patients with Relapsing Multiple Sclerosis: Results from the OPTIMUM Study of Ponesimod

被引：0
|
作者：
Keenan, A. [1 ]
Gandhi, K. [1 ]
Le, H. H. [1 ]
Turkoz, I. [1 ]
Guo, S. [2 ]
Liao, W.
Pelligra, C. G. [3 ]
机构：
[1] Janssen Pharmaceut, Titusville, NJ USA
[2] Evidera, Waltham, MA USA
[3] Evidera, Bogota, Colombia
来源：
MULTIPLE SCLEROSIS JOURNAL | 2022年 / 28卷 / 1_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P085
引用
收藏
页码：58 / 58
页数：1
相关论文
共 50 条
  • [1] Assessing the benefits of disease modifying therapy in relapsing multiple sclerosis using the MAGNIMS score: a post-hoc analysis of OPTIMUM study of ponesimod by early relapse status
    Gandhi, K.
    Pelligra, C. G.
    Keenan, A.
    Liao, W.
    Ait-Tihyaty, M.
    Guo, S.
    Turkoz, I.
    Kutch, M.
    Le, H. H.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 877 - 878
  • [2] Results of the Phase 3 OPTIMUM Study of Ponesimod Compared with Teriflunomide in Female Patients with Relapsing Multiple Sclerosis
    Jones, R.
    Turkoz, I.
    Ait-Tihyaty, M.
    DiBernardo, A.
    Houtchens, M.
    Havrdova, E.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (1_SUPPL) : 59 - 60
  • [3] Ponesimod compared with teriflunomide in female patients of childbearing age with relapsing multiple sclerosis: Results of the phase 3 OPTIMUM study
    Jones, R. R.
    Turkoz, I.
    Ait-Tihyaty, M.
    DiBernardo, A.
    Houtchens, M.
    Havrdova, E. K.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 460 - 461
  • [4] Effect of oral ponesimod on clinical disease activity and mri-based outcomes in patients with relapsing multiple sclerosis: phase 3 optimum study
    Kappos, L.
    Burcklen, M.
    Freedman, M.
    Fox, R.
    Havrdova, E. Kubala
    Hennessy, B.
    Hohlfeld, R.
    Lublin, F.
    Montalban, X.
    Pozzilli, C.
    Scherz, T.
    Linscheid, P.
    Pirozek-Lawniczek, M.
    Ford, L.
    Kracker, H.
    Wuerfel, J.
    Sprenger, T.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 151 - 152
  • [5] Efficacy and Safety of Ponesimod Compared with Teriflunomide in Female Patients with Relapsing Multiple Sclerosis: Findings from the Pivotal OPTIMUM Study
    Jones, Robyn R.
    Turkoz, Ibrahim
    Ait-Tihyaty, Maria
    Dibernardo, Allitia
    Houtchens, Maria K.
    Havrdova, Eva Kubala
    JOURNAL OF WOMENS HEALTH, 2024, 33 (04) : 480 - 490
  • [6] Effect on disability measures and msfc in patients with relapsing multiple sclerosis from the phase 3 ponesimod versus teriflunomide optimum study
    Fox, R.
    Kappos, L.
    Burcklen, M.
    Freedman, M.
    Havrdova, E.
    Hennessy, B.
    Hohlfeld, R.
    Lublin, F.
    Montalban, X.
    Pozzilli, C.
    Scherz, T.
    Linscheid, P.
    Ford, L.
    Pirozek-Lawniczek, M.
    Kracker, H.
    Sprenger, T.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 216 - 217
  • [7] Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study A Randomized Clinical Trial
    Kappos, Ludwig
    Fox, Robert J.
    Burcklen, Michel
    Freedman, Mark S.
    Havrdova, Eva K.
    Hennessy, Brian
    Hohlfeld, Reinhard
    Lublin, Fred
    Montalban, Xavier
    Pozzilli, Carlo
    Scherz, Tatiana
    D'Ambrosio, Daniele
    Linscheid, Philippe
    Vaclavkova, Andrea
    Pirozek-Lawniczek, Magdalena
    Kracker, Hilke
    Sprenger, Till
    JAMA NEUROLOGY, 2021, 78 (05) : 558 - 567
  • [8] Ponesimod Versus Teriflunomide in Relapsing Multiple Sclerosis: Efficacy Results from the OPTIMUM Phase 3 Randomised, Double-Blind Superiority Study
    Fox, R.
    Burcklen, M.
    Freedman, M. S.
    Havrdova, F. K.
    Hennessy, B.
    Hohlfeld, R.
    Lublin, F.
    Montalban, X.
    Pozzilli, C.
    Scherz, T.
    Linscheid, P.
    Pirozek-Lawniczek, M.
    Kracker, H.
    Sprenger, T.
    Kappos, L.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 338 - 338
  • [9] Outcome Reporting Bias in Clinical Trials Researching Disease-Modifying Therapy in Patients With Multiple Sclerosis
    Lemmens, Cynthia M. C.
    van Amerongen, Suzan
    Strijbis, Eva M.
    Killestein, Joep
    NEUROLOGY, 2024, 102 (06) : e208032
  • [10] Discontinuation of disease-modifying therapy for patients with relapsing-remitting multiple sclerosis: Effect on clinical and MRI outcomes
    Yano, Hajime
    Gonzalez, Cindy
    Healy, Brian C.
    Glanz, Bonnie, I
    Weiner, Howard L.
    Chitnis, Tanuja
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2019, 35 : 119 - 127
12345